Passive AD Immunotheraphy

What is Alzheimer's?

Alzheimer’s disease is the most common form of organic dementia. It affects roughly10% of the population over 65 and 40% of those over 85 years of age. Unlike other leading causes of death, mortality from Alzheimer’s disease is increasing. The number of cases is predicted to escalate dramatically over the next 2–3 decades as success in treating heart disease and cancer permits more individuals to reach the age of risk for dementias.

About Passive AD Test

The PassiveAD Test: Advanced Diagnostics in Alzheimer’s Disease

The Passive AD test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help physicians better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.

Step 1

Your physician
orders the
test and
schedules a
blood draw appointment

Step 2

Your blood
sample is sent
to the C₂N
laboratory for
analysis by
mass spectrometer

Step 3

Your physician
receives the
PassiveAD test
report and
discusses results
with you

Summary of Test and Benefits

Knowing that your symptoms are due to Alzheimer’s can help inform your physician to prescribe specific Alzheimer’s treatments in order to aid in the management of the disease.  If your symptoms are unlikely due to Alzheimer’s (e.g. a normal test result), your physician can search for other causes, some of which can be treated with different interventions.

Earlier detection provides the opportunity for earlier care options, including clinical trials. Many clinical trials for Alzheimer’s disease are looking for participants who show initial signs of cognitive impairment. You also may be eligible to enrol in clinical trials as a result of the PassiveAD test results.